PMID- 16392280
OWN - NLM
STAT- MEDLINE
DCOM- 20060215
LR  - 20190917
IS  - 0370-8179 (Print)
IS  - 0370-8179 (Linking)
VI  - 133
IP  - 5-6
DP  - 2005 May-Jun
TI  - [Metoprolol and atenolol in mild-to-moderate chronic heart failure: comparative 
      study].
PG  - 242-7
AB  - The clinical end-point of all causes of mortality and cardiovascular 
      hospitalisation (combined end-points) is a widely accepted indicator of heart 
      failure survival. The primary aim of this study was to examine the effects of 
      metoprolol and atenolol on combined end-points in patients with mild-to-moderate 
      heart failure. This study was designed to be comparative, prospective, and 
      random. The criteria for study inclusion were: age of 70 years or less, New York 
      Heart Association (NYHA) Functional Class II and III, and an ejection fraction of 
      the left ventricle of 40% or less. The patients (a total of 150) on therapy with 
      angiotensin-converting enzyme inhibitor and a diuretic were randomised into three 
      numerically equal therapy groups: 1) an atenolol group; 2) a metoprolol group; 
      and 3) a control group (without beta-blockers). The follow-up period was 12 
      months. The results were analysed using: the hi-square test, variance analyses, 
      Kaplan-Meier's model, Wilcox's statistics, and Cox's model. The cumulative 
      survival rate for patients treated with metoprolol was 88%, 78% for patients 
      treated with atenolol, and 48% for patients from the control group. It is clear 
      that the cumulative survival rate for patients treated with metoprolol and 
      atenolol is significantly higher compared to patients from the control group. In 
      addition, the survival rate of patients treated with metoprolol was considerably 
      higher compared to the survival rate of patients treated with atenolol. 
      Metoprolol has significantly reduced the relative risk of combined end-points 
      (71%) compared to atenolol (53%). The results of this comparative study clearly 
      indicate that metoprolol and atenolol have a favourable effect on the survival 
      rate of patients with chronic heart failure. In addition, metoprolol is 
      considerably more effective than atenolol.
FAU - Celic, Vera
AU  - Celic V
AD  - Clinical Medical Centre "Dr. Dragisa Misovic" - Dendinje, Belgrade. 
      celgoran@eunet.yu
FAU - Pencic, Biljana
AU  - Pencic B
FAU - Dekleva, Milica
AU  - Dekleva M
FAU - Dimkovic, Sinisa
AU  - Dimkovic S
FAU - Kocijancic, Maksimilijan
AU  - Kocijancic M
LA  - srp
PT  - Comparative Study
PT  - English Abstract
PT  - Journal Article
PT  - Randomized Controlled Trial
PL  - Serbia
TA  - Srp Arh Celok Lek
JT  - Srpski arhiv za celokupno lekarstvo
JID - 0027440
RN  - 0 (Adrenergic beta-Antagonists)
RN  - 50VV3VW0TI (Atenolol)
RN  - GEB06NHM23 (Metoprolol)
SB  - IM
MH  - Adrenergic beta-Antagonists/*therapeutic use
MH  - Atenolol/*therapeutic use
MH  - Female
MH  - Heart Failure/*drug therapy/mortality/physiopathology
MH  - Humans
MH  - Male
MH  - Metoprolol/*therapeutic use
MH  - Middle Aged
MH  - Survival Rate
EDAT- 2006/01/06 09:00
MHDA- 2006/02/16 09:00
CRDT- 2006/01/06 09:00
PHST- 2006/01/06 09:00 [pubmed]
PHST- 2006/02/16 09:00 [medline]
PHST- 2006/01/06 09:00 [entrez]
AID - 10.2298/sarh0506242c [doi]
PST - ppublish
SO  - Srp Arh Celok Lek. 2005 May-Jun;133(5-6):242-7. doi: 10.2298/sarh0506242c.